Vergent is a biotechnology company developing a tumor-targeted, fluorescent probe to help surgeons quickly identify and completely remove cancerous tissue during surgery. Surgery is often the first-line treatment for solid tumors and the prognosis of a procedure is highly correlated with achieving complete tumor removal. When injected prior to surgery, Vergent's molecularly-targeted probe binds to enzymes overexpressed in tumor tissue, activating a brightly fluorescing dye. The cancer 'lights up,' providing the surgeon a clear visual guide for the surgical removal of the tumor and associated metastases. Vergent's proprietary probe is under development for use in multiple cancers including lung, breast, ovarian, colorectal, and brain, among others.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/12/18 | $8,700,000 | Series A |
Spring Mountain Capital | undisclosed |
| 10/04/22 | $21,500,000 | Series B |
Colle Capital Intuitive Surgical Orlando Healthcare Ventures Rex Health Ventures Spring Mountain Capital Windham Venture Partners | undisclosed |
